newsfilter
← Latest News
GlobeNewswire·

RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial

RNXT
  • RenovoRx, Inc. (NASDAQ: RNXT) announced the enrollment of the first patient in the PRISM-TAMP investigator-initiated trial (IIT), with a second patient progressing toward treatment one week later.
  • The PRISM-TAMP study, sponsored by the University of Vermont (UVM), evaluates RenovoRx's Trans-Arterial Micro-Perfusion (TAMP) platform delivering gemcitabine via RenovoCath as neoadjuvant treatment for borderline Pancreatic Ductal Adenocarcinoma (PDAC).
  • UVM plans to enroll approximately 10 patients in the PRISM-TAMP trial, which is registered on ClinicalTrials.gov under identifier NCT07477418.
  • The primary objectives of the trial are to assess tumor regression, the impact on intraoperative surgical margins, and the overall safety and tolerability of delivering chemotherapy locally near the tumor site.
  • Leesa Gentry, Chief Clinical Officer of RenovoRx, stated that the trial marks a shift from concept to clinical execution for the IIT program while the company focuses on the Phase III TIGeR-PaC trial.
  • RenovoRx achieved full enrollment in the Phase III TIGeR-PaC trial in August 2026, with trial completion expected in the first half of 2027 and top-line data readout anticipated in the second half of 2027.
  • RenovoRx generated approximately $1.1 million in RenovoCath sales during 2025 and reported record quarterly revenue of $909,000 in the second quarter of 2026.
  • The intra-arterial gemcitabine product candidate (IAG) enabled by RenovoCath holds Orphan Drug Designation for pancreatic cancer and bile duct cancer, providing seven years of market exclusivity upon FDA approval.
  • RenovoCath is an FDA-cleared device intended for isolating blood flow, delivering therapeutic agents, and temporary vessel occlusion in applications such as chemotherapeutic drug infusion.